Oric Pharmaceuticals (NASDAQ:ORIC) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.05), Zacks reports.

Oric Pharmaceuticals Trading Up 6.4%

NASDAQ:ORIC opened at $8.00 on Wednesday. The company has a market capitalization of $829.20 million, a P/E ratio of -5.48 and a beta of 1.23. Oric Pharmaceuticals has a 12 month low of $7.23 and a 12 month high of $14.68. The firm has a fifty day simple moving average of $11.36 and a 200-day simple moving average of $10.98.

Insider Activity

In related news, CFO Dominic Piscitelli sold 77,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at $955,945.32. This represents a 52.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 105,000 shares of company stock valued at $1,432,952. 5.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ORIC shares. Leerink Partners started coverage on Oric Pharmaceuticals in a research note on Monday, October 5th. They set an “outperform” rating and a $26.00 target price on the stock. Citigroup increased their price target on Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright boosted their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

View Our Latest Report on ORIC

Oric Pharmaceuticals Company Profile

(Get Free Report)

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

Read More

Earnings History for Oric Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.